Tremfya Market Summary

The global Tremfya market size was estimated at USD 3.67 billion in 2024 and is projected to reach USD 7.29 billion by 2033, expanding at a compound annual growth rate (CAGR) of 7.60% from 2025 to 2033. The growing prevalence of chronic plaque psoriasis and psoriatic arthritis continues to be a major factor driving the demand for advanced biologic therapies.

These autoimmune conditions are becoming increasingly common worldwide, resulting in heightened demand for effective, long-term treatment solutions. Tremfya, a monoclonal antibody that selectively targets interleukin-23 (IL-23), has demonstrated strong clinical efficacy and sustained results in patients with moderate-to-severe disease. Its ability to deliver consistent outcomes and maintain a favorable safety profile has played a crucial role in gaining trust among healthcare professionals, especially dermatologists and rheumatologists who are at the forefront of managing these conditions.

Key Market Trends & Insights

• In 2024, the plaque psoriasis segment led the market with the highest revenue share of 87.0%. This dominance can be attributed to the widespread prevalence of moderate-to-severe plaque psoriasis and the growing preference for targeted biologic therapies that provide longer-lasting remission and improved quality of life compared to conventional treatments.
• The hospital pharmacies segment accounted for the largest revenue share of 51.2% in 2024. This is largely due to the structured processes involved in biologics procurement and administration within hospital settings. Specialist-driven prescribing patterns, comprehensive patient screening, and close monitoring for safety and efficacy make hospitals the preferred point of care for administering Tremfya to eligible patients requiring advanced therapeutic interventions.
• The online pharmacies segment is expected to grow at the fastest CAGR throughout the forecast period. This growth is driven by increasing digitization of healthcare services, rising adoption of e-commerce platforms for medication delivery, and consumer inclination toward the convenience of doorstep delivery for chronic disease treatments like Tremfya.
• Regionally, North America held the dominant position in the global Tremfya market in 2024, capturing 85.46% of total revenue. The region's leadership is supported by the high prevalence of psoriasis and psoriatic arthritis, a well-developed healthcare system, widespread biologic use, and the presence of major pharmaceutical players.
• Within North America, the United States is a key contributor to market growth, benefiting from early diagnosis rates, favorable insurance coverage, widespread adoption of biologics, and extensive direct-to-consumer pharmaceutical marketing strategies. These factors support faster market penetration and higher treatment adherence.
• In Europe, the Tremfya market continues to expand steadily, led by countries such as Germany, France, and the United Kingdom. Growth in this region is underpinned by well-established specialist networks, government-supported public health initiatives, and national formularies that encourage access to innovative therapies like Tremfya for eligible patients.
• The Asia Pacific region is expected to register the fastest CAGR of 15.73% during the forecast period. Rising disease awareness, increasing modernization of healthcare systems, greater affordability and access to biologics, and growing patient populations in countries like China, India, and Japan are key drivers of rapid growth in this region.
• In Latin America, the Tremfya market is experiencing moderate growth, particularly in countries like Brazil and Argentina. Growing awareness about biologic therapies, government investment in healthcare infrastructure, and rising acceptance of advanced treatments are supporting the market. However, challenges such as inconsistent regulatory timelines and varied reimbursement policies still limit broader market expansion in certain areas.
• The Middle East and Africa region is witnessing increasing demand for Tremfya, especially in nations such as Saudi Arabia, the United Arab Emirates, and South Africa. Growth is being driven by a rise in non-communicable diseases, improved insurance penetration, and the expansion of advanced hospital infrastructure. Government support for healthcare development is further enabling access to biologics.

Order a free sample PDF of the Tremfya Market Intelligence Study, published by Grand View Research.

Market Size & Forecast

• 2024 Market Size: USD 3.67 Billion
• 2033 Projected Market Size: USD 7.29 Billion
• CAGR (2025-2033): 7.60%
• North America: Largest market in 2024
• Asia Pacific: Fastest growing market

Key Companies & Market Share Insights

Johnson & Johnson Services, Inc. remains the key player in the Tremfya market, leveraging its strong global presence, robust regulatory approvals, and comprehensive distribution networks. Strategic pricing, innovative research, and effective supply chain operations influence competitive dynamics in this market. Emerging players such as Arven Pharmaceuticals from Turkey, Biocon from India, and MorphoSys from Germany are gradually expanding their presence by focusing on clinical development and cost-effective production.

These companies aim to challenge established players by introducing new formulations and targeting underserved markets. As healthcare providers increasingly seek affordable and effective treatment options, competition in the Tremfya market is expected to intensify. Overall, the market is projected to grow significantly throughout the forecast period.

Explore Horizon Databook – The world's most expansive market intelligence platform developed by Grand View Research.

Conclusion

The global Tremfya market is poised for steady growth, driven by the increasing prevalence of autoimmune conditions like plaque psoriasis and psoriatic arthritis. Tremfya’s strong clinical performance, targeting IL-23, continues to gain widespread acceptance among healthcare providers due to its long-lasting efficacy and safety. The market is led by North America, particularly the U.S., while Asia Pacific shows the fastest growth potential. Rising digital adoption, healthcare modernization, and evolving treatment guidelines further support global market expansion. As awareness, accessibility, and biologic affordability improve, Tremfya is expected to remain a vital therapeutic option in the evolving landscape of immunological treatment.